摘要
化疗、靶向治疗及抗血管治疗显著改善了晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的预后,但长期生存,特别是5年生存率仍不容乐观。随着对肿瘤免疫微环境认识的不断加深,以程序性死亡蛋白1(programmed cell death protein 1,PD-1)/程序性死亡蛋白配体1(programmed death-ligand 1,PD-L1)抑制剂为代表的免疫检查点抑制剂在晚期NSCLC患者中取得了突破性进展。此外,PD-1/PD-L1抑制剂与化疗、放疗、抗血管新生药物等的联合治疗策略正在积极探索中。本文从PD-1/PD-L1抑制剂单药治疗、联合治疗两方面综述PD-1/PD-L1抑制剂在晚期NSCLC中的研究进展。
Chemotherapy, targeted therapy and angiogenesis therapy have achieved significant improvement of overall survival in non-small cell lung cancer（NSCLC）. However, long time survival especially 5 years survival rate is still poor. With the understanding of tumor microenvironment, especially programmed cell death protein 1（PD-1）/programmed death-ligand 1（PD-L1） inhibitors showed durable anti-tumor efficacy in part of NSCLC patients. Besides that, enormous efforts are undergoing on combining strategy of PD-1/PD-L1 inhibitors with multiple treatment options such as chemotherapy, radiotherapy and anti-angiogenesis. Herein, we reviewed the available data on progress of PD-1/PD-L1 inhibitors monotherapy and combination therapy in this study.
作者
刘弋维
杨硕
任胜祥
LIU Yi-wei;YANG Shuo;REN Sheng-xiang(Department of Oncology,Shanghai Pulmonary Hospital,Tongji University,Shanghai 200433,China)
出处
《中国医学前沿杂志（电子版）》
2018年第7期8-16,共9页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
基金
国家自然科学基金(81772467)
